International Consensus Criteria Standardise T-PLL Diagnosis and Response Assessment
The T-PLL International Study Group published the first consensus guidelines for diagnosis, staging, treatment indication, and response assessment in T-cell prolymphocytic leukaemia. These standardised criteria are essential for enabling meaningful comparison across clinical trials and will support regulatory approval pathways for novel therapeutics in this rare T-cell malignancy.
The original study
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.
- Authors
- Staber PB, Herling M, Bellido M, Jacobsen ED, Davids MS, Kadia TM, et al.
- Journal
- Blood
- Type
- Journal Article, Review, Consensus Statement
- PMID
- 31292114
Original abstract
T-cell prolymphocytic leukemia (T-PLL) is a rare, mature T-cell neoplasm with a heterogeneous clinical course. With the advent of novel treatment options that will potentially change the management of patients with T-PLL, it has become necessary to produce consensus guidelines for the design and conduct of clinical trials. The T-PLL International Study group (TPLL-ISG) set out to define standardized criteria for diagnosis, treatment indication, and evaluation of response. These criteria will facilitate comparison of results from clinical trials in T-PLL, and will thus support clinical decision making, as well as the approval of new therapeutics by healthcare authorities.